Price Alert

Contineum Therapeutics In... (CTNM)

NASDAQ: CTNM · Real-Time Price · USD

11.67

0.81 (7.46%)

At close: Sep 26, 2025, 11:06 AM

7.46% (1D)

Bid	11.44
Market Cap	327.24M
Revenue (ttm)	n/a
Net Income (ttm)	-56.86M
EPS (ttm)	-2.07
PE Ratio (ttm)	-5.64
Forward PE	-3.89
Analyst	Buy
Dividends	n/a

Ask	14.14
Volume	32,071
Avg. Volume (20D)	289,379.1
Open	11.01
Previous Close	10.86
Day's Range	10.98 - 11.69
52-Week Range	3.35 - 20.24
Beta	1.19
Ex-Dividend Date	n/a

About CTNM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CTNM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CTNM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Contineum Therapeutics Inc. Class A Common Stock is scheduled to release its earnings on Nov 5, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+9.76%

Contineum Therapeutics shares are trading higher a... Unlock content with Pro Subscription

News

1 week ago · businesswire.com

Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...

1 month ago · zacks.com

Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 235.8% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is qu...

1 month ago · fool.com

Contineum (CTNM) Q2 R&D Jumps 78%